Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.35 | N/A | +14.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.35 | N/A | +14.66% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about future developments. They are focused on their clinical programs and maintaining progress.
Management highlighted ongoing development efforts and the importance of upcoming clinical trials.
They emphasized a commitment to advancing their pipeline despite current challenges.
Kodiak Sciences reported a larger-than-expected loss per share, which was a positive surprise compared to expectations, but they did not provide revenue figures. The stock reacted slightly down by 0.61%, indicating some investor caution. The lack of guidance may have contributed to the stock's decline as investors look for clearer direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RIGETTI COMPUTING IN
Mar 27, 2023